DOCSLIB.ORG

Galena Biopharma, Inc. (Exact Name of Registrant As Specified in Its Charter) ______

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Galena Biopharma, Inc. (Exact Name of Registrant As Specified in Its Charter) ______ ANNUAL REPORT 201 OUR MISSION GALENA BIOPHARMA DEVELOPS AND COMMERCIALIZES INNOVATIVE, TARGETED ONCOLOGY TREATMENTS THAT ADDRESS MAJOR UNMET MEDICAL NEEDS TO ADVANCE CANCER CARE. MANAGEMENT TEAM Mark J. Ahn, Ph.D., President & Chief Executive Officer Remy Bernarda, Vice President, Marketing & Communications Gavin Choy, Pharm.D., Senior Vice President, Clinical Operations & Cinical Science Ryan Dunlap, CPA, Vice President, Chief Financial Officer Brian Hamilton, M.D., Ph.D., Executive Vice President & Chief Medical Officer Robert Laliberte, MS, Vice President, Clinical Operations & Clinical Science Christopher Lento, Vice President, Sales & Commercial Operations Hana B. Moran, Ph.D., Senior Vice President, Regulatory & Compliance Patricia Murphy, Vice President, Regulatory Affairs & Compliance Mark W. Schwartz, Ph.D., Executive Vice President & Chief Operating Officer SCIENTIFIC ADVISORY BOARD COL George Peoples, M.D., F.A.C.S., Chief, Surgical Oncology, Brooke Army Medical Center; Director and Principal Investigator, Cancer Vaccine Development Program, San Antonio Military Medical Center Hope S. Rugo, M.D., Clinical Professor of Medicine, Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Care Center Robert Figlin, M.D., F.A.C.P., Dr. Figlin is a fellow of the American College of Physicians and the International Society for Biologic Therapy as well as a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Urological Association. Dr. Gabriel N. Hortobagyi, M.D., F.A.C.P., is a Professor of Medicine and Chairman of the Department of Breast Medical Oncology and holds the Nellie B. Connally Chair in Breast Cancer Research at the University of Texas MD Anderson Cancer Center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d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33958 _______________________________________________________ Galena Biopharma, Inc. (Exact name of registrant as specified in its charter) _______________________________________________________ Delaware 20-8099512 (State of incorporation) (I.R.S. Employer Identification No.) 4640 SW Macadam Ave., Suite 270, Portland, OR 97239 (Address of principal executive office) (Zip code) Registrant’s telephone number: (855) 855-4253 Securities registered pursuant to Section 12(b) of the Exchange Act: Title of Each Class Name of Exchange on Which Registered Common Stock, $0.0001 Par Value per Share The NASDAQ Capital Market Securities registered pursuant to Section 12(b) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10- K. Yes No Indicate by check mark whether the registrant has submitted electronically and posted on it corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for any such shorter time that the registrant was required to submit and post such files). Yes No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one): Large accelerated filer Accelerated filer Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No Based on the closing price of the Registrant's common stock as reported on the NASDAQ Capital Market, the aggregate market value of the Registrant's common stock held by non-affiliates on June 28, 2013 (the last business day of the Registrant's most recently completed second fiscal quarter) was approximately $185,711,000. As of February 28, 2014, Galena Biopharma, Inc. had outstanding 117,879,459 shares of common stock, $0.0001 par value per share, exclusive of treasury shares. GALENA BIOPHARMA, INC. FORM 10-K — FISCAL YEAR ENDED DECEMBER 31, 2013 INDEX Part Item Page No. No. Description No. I1Business 3 1A Risk Factors 13 1B Unresolved Staff Comments 41 2 Properties 41 3 Legal Proceedings 41 4 Mine Safety Disclosures 41 II 5 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 42 6 Selected Financial Data 45 7 Management's Discussion and Analysis of Financial Condition and Results of Operations 45 7A Quantitative and Qualitative Disclosures About Market Risk 55 II 8 Financial Statements and Supplementary Data 56 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosures 86 9A Controls and Procedures 86 9B Other Information 87 III 10 Directors, Executive Officers and Corporate Governance 89 11 Executive Compensation 89 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 89 13 Certain Relationships and Related Transactions, and Director Independence 89 14 Principal Accountant Fees and Services 89 Index to Exhibits 90 Signatures 94 EX-3.1 EX-3.2 EX-10.1 EX-31.1 EX-31.2 EX-32.1 1 "SAFE HARBOR" STATEMENT Some of the information contained in this annual report may include forward-looking statements that reflect our current views with respect to our commercial and development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. We make these statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “estimate,” “may,” “should,” “anticipate,” “will” and similar statements of a future or forward-looking nature identify forward-looking statements for purposes of the federal securities laws or otherwise. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events
Load more

Recommended publications
  • BIOWORLD TODAY Inquiry
    BIOWORLDTM TODAY THE DAILY BIOPHARMACEUTICAL NEWS SOURCE JUNE 30 , 2016 BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS VOLUME 27, NO. 126 LIPID JAM NOT OVER EASILY STOPPED FOR FUTILITY Waffle house? FDA Galena Biopharma implodes as PRESENT review fidgets endpoint, puts cancer vaccine Neuvax future in doubt outcome details; By Jennifer Boggs, Managing Editor Esperion grilled on holdup With the bulk of Galena Biopharma Inc.’s value riding on cancer vaccine Neuvax By Randy Osborne, Staff Writer (nelipepimut-S), the firm’s shares predictably plunged to a new 52-week low Wednesday as an independent data monitoring committee (IDMC) recommended the Analysts had plenty of questions but PRESENT phase III study in breast cancer be stopped for futility following a planned Esperion Therapeutics Inc. offered few interim analysis. But it’s the troubling language in the IDMC’s letter, suggesting the answers regarding the FDA’s stalling on placebo arm might actually have bested the treatment arm, that could signal the end oral, once-daily bempedoic acid (ETC- of the road for Neuvax. 1002) for lipid lowering, after the agency See Galena, page 3 See Esperion, page 4 CHINA DEALS AND M&A IN THE CLINIC Pfizer invests in Asia Merck strikes cancer SUPER ‘NOVA’ with $350M biotech vaccines deal with Tesaro shares blast plant in Hangzhou Moderna, delivering off as niraparib hits By Haky Moon, Staff Writer $200M up front PFS in ovarian cancer HONG KONG – China’s economy may By Michael Fitzhugh, Staff Writer By Marie Powers, News Editor be slowing down, but multinationals Findings from the phase III NOVA trial are positioning themselves to leverage Cancer vaccines tailored to fit tumor- specific profiles are at the heart of a new of niraparib in women with recurrent it as best they can while navigating a ovarian cancer blasted shares of still-complex regulatory environment.
    [Show full text]
  • Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote
    As of 4/23/2013 Schedule subject to change Monday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room April 22 Merck KLOX Technologies Immune Design 1:00 PM Leading Biotech/Big Pharma Medical Devices Vaccines Eli Lilly NewSouth Innovations Syntiron 1:15 PM Leading Biotech/Big Pharma University/Academia Vaccines Amgen Radius Health BioCrea 1:30 PM Leading Biotech/Big Pharma Musculoskeletal Neurology/CNS Nat. Inst. of Neurological Dis. & Stroke Cytokinetics Xenon Pharmaceuticals 1:45 PM Neurology/CNS Musculoskeletal Neurology/CNS Curis OrgaNext Research BV Trigemina 2:00 PM Oncology Regenerative Medicine Neurology/CNS Verastem Flexion Therapeutics Neurocrine Biosciences 2:15 PM Oncology Musculoskeletal Hormone Therapy/CNS Michael J. Fox Foundation Antisense Pharma GmbH Versartis 2:30 PM Non-profit/Patient Advocacy Oncology Hormone Therapy Takeda Pharmaceutical Company TBD KODE Biotech 2:45 PM Leading Biotech/Big Pharma Drug Delivery Resverlogix Corp. Advaxis Q Chip 3:00 PM Cardiovascular Disease Oncology Drug Delivery Grünenthal GmbH Array BioPharma 3:15 PM Neurology/CNS Oncology/Drug Discovery Discovery Labs Mersana Therapeutics 3:30 PM Drug Delivery/Pulmonary Oncology Bayer HealthCare Igenica 3:45 PM Leading Biotech/Big Pharma Oncology Presentations are open to all Convention attendees and are located outside the main entrance of the BIO Business Forum As of 4/23/2013 - Schedule subject to change Tuesday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Chicago Blackhawks Room April 23 Pfizer 8:00 AM Leading Biotech/Big Pharma
    [Show full text]
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
    [Show full text]
  • Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
    Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential The Life Sciences Report www.TheLifeSciencesReport.com 05/02/2013 In January 2013, The Life Sciences Report debuted its biotech COMPANIES MENTIONED Watchlist, which outlined ideas for investors keyed to catalysts in Amarin Corp. the drug development process that typically move biotechnology Astellas Pharma Inc. stocks. All stocks are affected by catalysts, but nowhere do they Bayer provide more leverage (or deleverage) than in biotech. We Cardinal Health Inc. predicted the new year would present legitimate prospects for Celsion Corp. portfolio growth. So far, that has been the case. Although the party has given Galena Biopharma Inc. way to some fatigue, the punch bowl is still on the table and the biotech Hyperion Therapeutics upswing continues. Inc. Medivation Inc. Source: George S. Mack of The Life Sciences Report Navidea Biopharmaceuticals Inc. Back in January, our friends and collaborators at San Diego-based Sagient Novartis AG Research, publishers of the BioMedTracker, offered important information about Onyx Pharmaceuticals market-moving data and events that can make or break smaller companies. In Inc. addition, a group of key biotech analysts weighed in on their best ideas—17 stocks Peregrine Pharmaceuticals Inc. in all. It was the perfect storm of individual ideas combined with a biotech wind from Pfizer Inc. 2012 still billowing the sails. As of April 22, the NASDAQ Biotechnology (NBI) Pharmacyclics Inc. index is up 26.6%. Have the biotech companies that made inaugural Biotech Prana Biotechnology Ltd. Watchlist—and their stocks—met the targets identified in the first quarter of 2013? Sangamo BioSciences Are there new catalysts? Check out the progress in the updated April 2013 Biotech Inc.
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Making the Capital Connections
    9 The Data-Driven Future of Genomics: 5 Minutes with Edico Genome’s CEO LifeLines 11 Navigating a New Policy Year For the California Life Science Community Turning Scientific Discoveries 17 into Successful Companies Making the Capital Connections VOLUME 27, ISSUE 1 Spring 2018 WELCOME IN THIS ISSUE By Joe Panetta, President and CEO, Biocom 4 Cover Story: Making the Capital Connections 9 Guest: The Data-Driven Future of Genomics: 5 Minutes with Edico Genome’s CEO 11 Public Policy: Navigating a Nwq Policy Year Greetings and welcome to our spring 2018 issue of LifeLines! The theme of this issue 13 Biocom Bay Area: Future-Focused and Well Positioned for Continued Success is investment. Investment in our programs and services, and exciting investments in the 15 Biocom LA: Why is Biocom Investing in LA? growth of our association, our members, and in our network of companies, academic 17 Biocom Institute: Turning Scientific Discoveries and research institutes and service providers across the globe. I can proudly declare into Successful Companies that we have now exceeded 1,000 members. In keeping with this growth, our staff 18 Upcoming Biocom Events has expanded to nearly 50 employees and our budget is approaching $10 million 20 Guest: MiraCosta College Launches Inaugural annually. Our footprint now includes members from California, Japan, and across the Biomanufacturing Bachelor's Program EU. This success and our deep bench of talent provide us the power to continue to 21 Biocom Purchasing Group: Investing in expand successfully into markets in the greater Los Angeles area, where we now have Your Success 125 members, and to the north in the San Francisco Bay Area, where we have more 23 San Diego Festival of Science & Engineering: than 200 members.
    [Show full text]
  • 8Th Annual BIO Investor Forum
    Monday Conrad Duke of Windsor Park South Basildon East Foyer Jade/Astor February 11, 2013 4th Floor 3rd Floor 7:00 – 7:55am Networking Breakfast: Grand Ballroom 8:00 – 8:45am Fireside Chat with Robert Hugin, Chairman and CEO, Celgene Corporation (Astor) Oxygen Proteon Therapeutics 9:00 – 9:25am Innovus Pharma Galena BioPharma GTx Biotherapeutics Tobira Therapeutics Show Me the Money: Reimbursement in an ACA World Transition Regado Biosciences 9:30 – 9:55am Verastem Advaxis ChemoCentryx (Jade) Therapeutics ALS TDI (PAG) CoLucid Pharmaceuticals ImmunoCellular 10:00 – 10:25am Advanced Cell Technology TBD Rigel Pharmaceuticals Actinium Pharmaceuticals Therapeutics Onconova Therapeutics Furiex 10:30 – 10:55am ReNeuron GENFIT NPS Pharmaceuticals Oncology: uniQure Pharmaceuticals Panning for Gold—Prospecting Fate Therapeutics Lexicon the Pancreatic Pipeline 11:00 – 11:25am Palatin Technologies CEL-SCI Corporation Repros Therapeutics Zafgen Pharmaceuticals (Jade) NovaBay Provectus LL Society (PAG) Tonix 11:30 – 11:55am Agenus Pharmaceuticals Pharmaceuticals Five Prime Therapeutics Pharmaceuticals 12:00 – 12:55pm Opening Plenary Session: Word on the Street – Buy-Side View for 2013 (Jade) – Box Lunch Catabasis Pharmaceuticals Fireside Chat with John Lechleiter, 1:00 – 1:25pm Anteo Diagnostics Atossa Genetics Targacept Synergy Pharmaceuticals Promedior Chairman, President & CEO, Eli Lilly KineMed (Astor; 1:00-1:45pm) 1:30 – 1:55pm ProMetic Life Sciences CytRx Corporation Biotie Therapies Cytokinetics TVAX Biomedical Good Start Genetics 2:00 – 2:25pm
    [Show full text]
  • HC Schedule 11-29-13V3.Xlsm
    Schedule as of: November 29, 2013 Schedule is subject to change. 25th Annual Piper Jaffray Healthcare Conference Tuesday, December 3 - Wednesday, December 4, 2013 New York Palace Hotel, New York Tuesday, Track One Track Two Track Three Track Four Track Five Track Six Track Seven December 3 Holmes 1&2 - 4th floor Spellman - 5th floor Hubbard 2 - 5th floor Louis - 4th floor Rutherford - 4th floor Kennedy 1 - 4th floor Kennedy 2 - 4th floor Registration – Villard Foyer, 2nd Floor Public & Private Company 7:30 Private Company Track Continental Breakfast – Reid Salon, 2nd Floor Track MWI Veterinary Supply, Quality Systems, Inc. Osiris Therapeutics, Galena Biopharma, Inc. 8:00 - 8:30 ResMed Inc. (RMD) Akorn, Inc. (AKRX) 8:10 bioTheranostics, Inc. Inc. (MWIV) (QSII) Inc. (OSIR) (GALE)* Regeneron 8:30 Good Start Genetics, Inc. SCI Solutions, Inc. Boston Scientific IDEXX Laboratories Inc. Jazz Pharmaceuticals, Inc. ArthroCare 8:30 - 9:00 Pharmaceuticals Inc. Corporation (BSX) (IDXX) (JAZZ) Corporation (ARTC) (REGN) 8:50 Neostem, Inc. (NBS)* Accellent, Inc. Smith & Nephew plc Impax Laboratories, Inc. 9:00 - 9:30 Illumina, Inc. (ILMN) MEDNAX, Inc. (MD) Endocyte, Inc. (ECYT) 9:10 LCA-Vision Inc. (LCAV)* Apollo Endosurgery, Inc. (SNN) (IPXL) 9:30 Venaxis, Inc. (APPY)* California Stem Cell, Inc. St. Jude Medical, Inc. Quest Diagnostics Hill-Rom Holdings, Inc. Cytokinetics, 9:30 - 10:00 Theravance Inc. (THRX) (STJ) Incorporated (DGX) (HRC) Incorporated (CYTK) Repligen Corporation Kadmon Corporation, 9:50 (RGEN)* LLC OncoMed ACADIA Pharmaceuticals Wright Medical Group, Ampio Pharmaceuticals, Curaspan Health Group, 10:00 - 10:30 Mallinckrodt plc (MNK) Pharmaceuticals, Inc. 10:10 Inc. (ACAD) Inc. (WMGI) Inc.
    [Show full text]
  • The Top 100 June, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen
    The Top 100 June, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. ASCMA Ascent Capital Group, Inc. Class A Consumer Discretionary CHTR Charter Communications, Inc. Class A Consumer Discretionary GPRO GoPro, Inc. Class A Consumer Discretionary LGF Lions Gate Entertainment Corp. Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary RKDA Arcadia Biosciences, Inc. Consumer Staples BCEI Bonanza Creek Energy, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy GPRE Green Plains Inc. Energy GST Gastar Exploration, Inc. Energy LGCY Legacy Reserves LP Energy SLCA U.S. Silica Holdings, Inc. Energy SWN Southwestern Energy Company Energy SXE Southcross Energy Partners, L.P. Energy SYRG Synergy Resources Corporation Energy WLL Whiting Petroleum Corporation Energy WMB Williams Companies, Inc. Energy XEC Cimarex Energy Co. Energy ACAD ACADIA Pharmaceuticals Inc. Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADRO Aduro BioTech, Inc. Health Care ADXS Advaxis, Inc. Health Care AGEN Agenus Inc. Health Care AGIO Agios Pharmaceuticals, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ALXN Alexion Pharmaceuticals, Inc. Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care AVGR Avinger, Inc. Health Care AXDX Accelerate Diagnostics, Inc. Health Care BLUE bluebird bio, Inc. Health Care BMRN BioMarin Pharmaceutical Inc. Health Care CARA Cara Therapeutics Inc Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CSU Capital Senior Living Corporation Health Care CTIC CTI BioPharma Corp. Health Care CYTK Cytokinetics, Incorporated Health Care DEPO Depomed, Inc.
    [Show full text]
  • Medicines, Markets and the Flash Mob: Issues and Implications for Tomorrow’S Biopharma Enterprise
    Medicines, Markets and the Flash Mob: Issues and Implications for Tomorrow’s Biopharma Enterprise SLA Pharma Health Tech Meeting Baltimore, MD June 9, 2018 Today’s Messages Medicines Markets …Put a Ring on It …Just Meh The Flash Mob …That “Blue Ocean” Strategy? Forget it! Biopharma Today: Evolution or Revolution? THE CHOICE ? • Health care is messy and institutionalized • Efficiency gains from BIG DATA • High barriers to entry: a risky, public good • Serial disrupter: Amazon is a ”loss leader” taking out retail segments with full price • Innovation: a partnering series of cumulative transparency steps • Will pharma retain its capacity to adapt – at • Exploitable gaps in Rx distribution – mail its own historically leisurely pace? order and cash pay generics • Challenge: health care is built on silo third-party transactions –alignment on incentives? 3 Pharma intelligence | informa Our 2018 Predictions…So Far M&A is Back on the Table Federal Legislation: A Mixed Bag for Pharma Trump’s Pharma Policy: Still No Medicare Price Negotiations Working with a Re-Energized FDA Payers Get Serious: Define and Deliver Value Manage a Controlled Rollout for Advanced Therapies Threats to US Lead in World-Class Drug Innovation Trump’s Teflon Tweets: Pharma Discovers it Doesn’t Stick 4 Pharma intelligence | informa Pharma Faces the Fiscal Cliff: Gross US Federal Debt 2018-2028 DRUG 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 DEBT Trillions $ 21.4 22.5 23.7 24.9 26.2 27.5 28.7 30.0 31.4 32.5 33.9 DEBT % GDP 78.0 79.3 80.9 83.1 85.7 87.9 89.6 91.5
    [Show full text]
  • Companies That Exploit Animals ©2019 Crueltyfreeinvesting.Org Title Stock Exchange Stock Symbol Animal Usage 1-800 FLOWERS.COM, Inc
    Companies That Exploit Animals ©2019 CrueltyFreeInvesting.org Title Stock Exchange Stock Symbol Animal Usage 1-800 FLOWERS.COM, Inc. NASDAQ FLWS Meat/Dairy/Eggs 22nd Century Group, Inc AMEX XXII Animal Testing 3M Company NYSE MMM Animal Testing 500.com Limited NYSE WBAI Entertainment|Tangential A. Schulman, Inc. NASDAQ SHLM Animal Testing ABAXIS, Inc. NASDAQ ABAX Animal Testing ABB Ltd NYSE ABB Tangential Abbott Laboratories NYSE ABT Animal Testing|By-product AbbVie Inc. NYSE ABBV Animal Testing Abeona Therapeutics Inc. NASDAQ ABEO Animal Testing Abercrombie & Fitch Company NYSE ANF Leather/Hide/Fur ABIOMED, Inc. NASDAQ ABMD Animal Testing AC Immune SA NASDAQ ACIU Animal Testing Acacia Research Corporation NASDAQ ACTG Animal Testing ACADIA Pharmaceuticals Inc. NASDAQ ACAD Animal Testing Acasti Pharma, Inc. NASDAQ ACST Animal Testing B&G Foods, Inc. NASDAQ BGS Meat/Dairy/Eggs Balchem Corporation NASDAQ BCPC Animal Testing|By-product|Pet Industry Alexion Pharmaceuticals, Inc. NASDAQ ALXN Animal Testing|Meat/Dairy/Eggs Amazon.com, Inc. NASDAQ AMZN Entertainment|Leather/Hide/Fur|Meat/Dairy/Eggs American Airlines Group, Inc. NASDAQ AAL Meat/Dairy/Eggs Amgen Inc. NASDAQ AMGN Animal Testing Bed Bath & Beyond Inc. NASDAQ BBBY Animal Testing|By-product|Leather/Hide/Fur|Tangential Biogen Inc. NASDAQ BIIB Animal Testing C.H. Robinson Worldwide, Inc. NASDAQ CHRW Meat/Dairy/Eggs|Tangential Celgene Corporation NASDAQ CELG Animal Testing Costco Wholesale Corporation NASDAQ COST Leather/Hide/Fur|Meat/Dairy/Eggs DENTSPLY SIRONA Inc. NASDAQ XRAY Animal Testing Dollar Tree, Inc. NASDAQ DLTR Leather/Hide/Fur|Meat/Dairy/Eggs eBay Inc. NASDAQ EBAY Leather/Hide/Fur|Meat/Dairy/Eggs|Pet Industry Endo International plc NASDAQ ENDP Animal Testing Garmin Ltd.
    [Show full text]
  • Cytrx Corporation (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) T ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15327 CytRx Corporation (Exact name of Registrant as specified in its charter) Delaware 58-1642740 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 11726 San Vicente Blvd, Suite 650, Los Angeles, California 90049 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (310) 826-5648 ________________ Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered Common Stock, $0.001 par value per share The NASDAQ Capital Market Series A Junior Participating Preferred Stock Purchase Rights Securities Registered Pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer (as defined in Securities Act Rule 405). Yes £ No R Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934. Yes £ No T Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]